Autologous Epstein-Barr virus-specific T-cell therapy (Atara Biotherapeutics)
N/A
Report date: 2022/01/14 13:23:58
Base Information
Drug NameAutologous Epstein-Barr virus-specific T-cell therapy (Atara Biotherapeutics)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAtara Biotherapeutics IncMemorial Sloan Kettering Cancer Center
China Registration ClassN/A
Develop Information
Active CompaniesAtara Biotherapeutics Inc
Inactive CompaniesMemorial Sloan Kettering Cancer Center
Active Indications
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A